These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 32862597)
1. Doxorubicin loaded liposomes for lung tumor targeting: in vivo cell line study in human lung cancer. Guo Y; Zhu Q; Shi J; Li Y; Fu D; Qiao D; Chen S; Yang Y; Wang Y J BUON; 2020; 25(3):1504-1511. PubMed ID: 32862597 [TBL] [Abstract][Full Text] [Related]
2. GE11-modified liposomes for non-small cell lung cancer targeting: preparation, ex vitro and in vivo evaluation. Cheng L; Huang FZ; Cheng LF; Zhu YQ; Hu Q; Li L; Wei L; Chen DW Int J Nanomedicine; 2014; 9():921-35. PubMed ID: 24611009 [TBL] [Abstract][Full Text] [Related]
3. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model. Moosavian SA; Abnous K; Badiee A; Jaafari MR Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819 [TBL] [Abstract][Full Text] [Related]
4. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment. Zou Y; Xia Y; Meng F; Zhang J; Zhong Z Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299 [TBL] [Abstract][Full Text] [Related]
5. Photosensitizer-Doped and Plasma Membrane-Responsive Liposomes for Nuclear Drug Delivery and Multidrug Resistance Reversal. Zhu YX; Jia HR; Duan QY; Liu X; Yang J; Liu Y; Wu FG ACS Appl Mater Interfaces; 2020 Aug; 12(33):36882-36894. PubMed ID: 32666795 [TBL] [Abstract][Full Text] [Related]
6. Tuftsin-Bearing Liposomes Co-Encapsulated with Doxorubicin and Curcumin Efficiently Inhibit EAC Tumor Growth in Mice. Murugesan K; Srinivasan P; Mahadeva R; Gupta CM; Haq W Int J Nanomedicine; 2020; 15():10547-10559. PubMed ID: 33414637 [TBL] [Abstract][Full Text] [Related]
7. Synergistic Antitumor Efficacy Mediated by Liposomal Co-Delivery of Polymeric Micelles of Vinorelbine and Cisplatin in Non-Small Cell Lung Cancer. Wang S; Gou J; Wang Y; Tan X; Zhao L; Jin X; Tang X Int J Nanomedicine; 2021; 16():2357-2372. PubMed ID: 33790554 [TBL] [Abstract][Full Text] [Related]
8. Effects of surface displayed targeting ligand GE11 on liposome distribution and extravasation in tumor. Tang H; Chen X; Rui M; Sun W; Chen J; Peng J; Xu Y Mol Pharm; 2014 Oct; 11(10):3242-50. PubMed ID: 25181533 [TBL] [Abstract][Full Text] [Related]
9. Preparation and characteristics of lipid nanoemulsion formulations loaded with doxorubicin. Jiang SP; He SN; Li YL; Feng DL; Lu XY; Du YZ; Yu HY; Hu FQ; Yuan H Int J Nanomedicine; 2013; 8():3141-50. PubMed ID: 23990722 [TBL] [Abstract][Full Text] [Related]
10. Preclinical study of Doxorubicine-loaded liposomal drug delivery for the treatment of head and neck cancer: Optimization by Box-Behnken statistical design. Yang B Acta Biochim Pol; 2020 Jun; 67(2):149-155. PubMed ID: 32506868 [TBL] [Abstract][Full Text] [Related]
11. The application of EDTA in drug delivery systems: doxorubicin liposomes loaded via NH4EDTA gradient. Song Y; Huang Z; Song Y; Tian Q; Liu X; She Z; Jiao J; Lu E; Deng Y Int J Nanomedicine; 2014; 9():3611-21. PubMed ID: 25120359 [TBL] [Abstract][Full Text] [Related]
13. Liposomal nitrooxy-doxorubicin: one step over caelyx in drug-resistant human cancer cells. Pedrini I; Gazzano E; Chegaev K; Rolando B; Marengo A; Kopecka J; Fruttero R; Ghigo D; Arpicco S; Riganti C Mol Pharm; 2014 Sep; 11(9):3068-79. PubMed ID: 25057799 [TBL] [Abstract][Full Text] [Related]
14. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation. Shaji J; Menon I Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699 [TBL] [Abstract][Full Text] [Related]
15. Enhanced anticancer activity in vitro and in vivo of luteolin incorporated into long-circulating micelles based on DSPE-PEG2000 and TPGS. Yan H; Wei P; Song J; Jia X; Zhang Z J Pharm Pharmacol; 2016 Oct; 68(10):1290-8. PubMed ID: 27465923 [TBL] [Abstract][Full Text] [Related]
16. EGFR Targeting of Liposomal Doxorubicin Improves Recognition and Suppression of Non-Small Cell Lung Cancer. Moles E; Chang DW; Mansfeld FM; Duly A; Kimpton K; Logan A; Howard CB; Thurecht KJ; Kavallaris M Int J Nanomedicine; 2024; 19():3623-3639. PubMed ID: 38660023 [TBL] [Abstract][Full Text] [Related]
17. Liposomal doxorubicin loaded PLGA-PEG-PLGA based thermogel for sustained local drug delivery for the treatment of breast cancer. Cao D; Zhang X; Akabar MD; Luo Y; Wu H; Ke X; Ci T Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):181-191. PubMed ID: 30686051 [TBL] [Abstract][Full Text] [Related]
18. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity. Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852 [TBL] [Abstract][Full Text] [Related]
19. GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers. Xu WW; Liu DY; Cao YC; Wang XY Int J Nanomedicine; 2017; 12():6461-6470. PubMed ID: 28919747 [TBL] [Abstract][Full Text] [Related]
20. Selenium-functionalized liposomes for systemic delivery of doxorubicin with enhanced pharmacokinetics and anticancer effect. Xie Q; Deng W; Yuan X; Wang H; Ma Z; Wu B; Zhang X Eur J Pharm Biopharm; 2018 Jan; 122():87-95. PubMed ID: 29032193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]